In the June 2008 supplement, in three articles in which Holger Schünemann is author or coauthor, “Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (); “Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (); and “Grades of Recommendation for Antithrombotic Guidelines: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (), the Conflict of Interest statement that appears at the end of the text in the print edition is wrong. It has been updated in the online edition and those versions of the articles should be used. The Conflict of Interest statement in each article should read: Dr. Schünemann reports no personal payments from for-profit organizations, but he received research grants and/or honoraria that were deposited into research accounts or received by a research group that he belongs to from AstraZeneca (research grant, honoraria), Amgen (research grant), Barilla (research grant), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), Roche (honorarium) and UnitedBioSource (honorarium) for development or consulting regarding quality of life instruments for chronic respiratory diseases and as lecture fees related to the methodology of evidence based practice guideline development and/or research methodology. He is documents editor for the American Thoracic Society and senior editor of the American College of Chest Physicians Antithrombotic and Thrombolytic Therapy Guidelines and both organizations receive funding from for-profit organizations. Other institutions or organizations that he is affiliated with likely receive funding from for-profit sponsors that are supporting infrastructure and research that may serve his work.